Ionis Q4 2024 Earnings Report

Ionis Q4 2024 Earnings Report showed a revenue decline and increased losses, but the company exceeded guidance and launched its first independent medicine.

Key Takeaways

Ionis Pharmaceuticals reported Q4 2024 revenue of $227,000,000, a 30.15% decline YoY. The company posted a net loss of $104,000,000, compared to a loss of $9,000,000 in Q4 2023. Despite these losses, Ionis exceeded its financial guidance and launched TRYNGOLZA, its first independently commercialized product.

Revenue declined by 30.15% YoY to $227,000,000.

Net loss increased to $104,000,000 from $9,000,000 YoY.

The company launched TRYNGOLZA, its first independent product.

Ionis exceeded its 2024 financial guidance.

Total Revenue

$227M

Previous year: $325M

-30.2%

EPS

-$0.43

Previous year: -$0.06

+616.7%

Operating Margin

-48.46%

Previous year: -1.85%

+2519.5%

Cost of Sales

$4M

Previous year: $3M

+33.3%

Ionis Revenue

Ionis EPS

Ionis Revenue by Segment

Forward Guidance

Ionis expects a shift toward increasing commercial revenue in 2025, investing in independent product launches while maintaining a strong financial position.

Positive Outlook

Revenue expected to exceed $600,000,000 in 2025.
Company shifting toward increasing commercial revenue sources.
Continued investment in TRYNGOLZA and upcoming product launches.
Cash position expected to remain strong at ~$1,700,000,000.
Pipeline progress with multiple upcoming clinical milestones.

Challenges Ahead

Operating loss expected to be below $495,000,000.
R&D expenses expected to remain high due to ongoing trials.
Market acceptance of new products remains uncertain.
Regulatory risks could impact launch timelines.
Potential competition from other biotechnology firms.